OC
IONS icon

Oppenheimer & Co’s Ionis Pharmaceuticals IONS Stock Holding History

Oppenheimer & Co’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-14,560
Closed -$539K – 1419
2022
Q2 		$539K Sell
14,560
-2,000
-12% -$75.4K 0.01% 891
2022
Q1 		$613K Sell
16,560
-1,798
-10% -$58.9K 0.01% 927
2021
Q4 		$559K Sell
18,358
-2,769
-13% -$87.2K 0.01% 993
2021
Q3 		$709K Sell
21,127
-221
-1% -$8.33K 0.01% 874
2021
Q2 		$852K Buy
+21,348
New +$836K 0.02% 814
2019
Q2 		– Sell
-4,715
Closed -$383K – 1338
2019
Q1 		$383K Buy
+4,715
New +$304K 0.01% 929
2015
Q3 		– Sell
-4,011
Closed -$231K – 1410
2015
Q2 		$231K Sell
4,011
-17,211
-81% -$1.09M 0.01% 1214
2015
Q1 		$1.35M Sell
21,222
-1,346
-6% -$91.3K 0.04% 531
2014
Q4 		$1.39M Buy
+22,568
New +$1.11M 0.04% 509

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Oppenheimer & Co's IONS Position: Q3 2022 in Review

Oppenheimer & Co sold out of Ionis Pharmaceuticals (IONS) in Q3 2022, closing a stake of 14,560 shares — an estimated $539K sold.

Oppenheimer & Co first reported a position in IONS in Q4 2014 and held it in 9 quarters. The position peaked at $1.39M in Q4 2014. 349 funds tracked by Wall St. Rank hold IONS as of Q3 2022.

  • Oppenheimer & Co reported no remaining Ionis Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Oppenheimer & Co sold 14,560 Ionis Pharmaceuticals shares in Q3 2022, an estimated $539K.
  • Oppenheimer & Co first reported a position in Ionis Pharmaceuticals in Q4 2014 and held it in 9 quarters.
  • Oppenheimer & Co's Ionis Pharmaceuticals position peaked at $1.39M in Q4 2014.
  • 349 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2022.

Based on Oppenheimer & Co's 13F filing for Q3 2022, filed 14 Nov 2022.